OptiBiotix Signs Major Supply Agreement for its Microbiome Modulating Cholesterol-Reduction Probiotic

d6d4fdd0-bcf5-4480-8f73-4ee148db27dbarticleimage.jpg

19 Jun 2017 --- Life sciences company OptiBiotix has signed a three-year supply agreement with HLH BioPharma Vertriebs GmbH for its cholesterol-reducing LPLDL probiotic supplement. Research into the LPLDL probiotic, presented at Vitafoods Europe in May 2017, demonstrated that it is a safe natural ingredient which reduces blood pressure and cholesterol, key determinates of cardiovascular risk. 

According to the company, the probiotic was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. This research was carried out by Glenn Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading.

Stephen O’Hara, CEO of OptiBiotix, comments, “The development of our LPLDL probiotic product has made cholesterol reduction through microbiome modulation a reality, and we are thrilled to be working with HLH, one of Europe’s leading suppliers to the pharmacy market, on this product. The ability to create designer active ingredients which can modify an individual’s microbiome to improve health places OptiBiotix at the forefront of global microbiome research and product development, and we anticipate many more opportunities for the LPLDL probiotic.”

Microbiome modulators in the form of probiotic supplements, like LPLDL, may be the way forward for managing long-term conditions like cardiovascular disease (CVD). The reduction of both LDL cholesterol and blood pressure is key for managing the risk of CVD. The combination of high blood pressure and cholesterol deposition may lead to the chronic inflammation and hardening of the walls of the blood vessels, which greatly increases the probability of suffering a cardiovascular event. Recent research, presented at the European Society of Cardiology Congress 2016, demonstrated that reducing LDL cholesterol and blood pressure can reduce the lifetime risk of cardiovascular disease by nearly 90%.

The supply agreement grants HLH a non-exclusive license to produce, package, and commercialize products containing the LPLDL strain, and follows HLH’s recent order for 100,000 units of LPLDL. HLH has over 20 years’ experience in the distribution of probiotic and natural products under the brand names Lactobact and Casa Sana and is one of Europe’s leading suppliers of probiotics to the pharmacy market. LPLDL will be supplied as bulk capsules which will be packaged and branded as part of HLH’s market leading Lactobact brand.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Business News

Fermentalg reports on Q1 revenue as US expansion begins

20 Apr 2018 --- Fermentalg, a French supplier of microalgae for nutrition and health, has reported first-quarter revenue of €232k whereas no income was recorded in Q1 2017. As of 31 March 2018, Fermentalg held gross cash and cash equivalents of €19.5 million compared to €21.8 million at 31 December 2017. Cash burn amounted to a €2.5 million outflow, stable compared to the previous quarter (excluding financing activities) and down €0.5 million from Q1 2017. Q1 was marked by progress achieved in bringing to market its DHA ORIGINS range of algal oils naturally rich in omega 3, as well as a US distribution agreement with Stauber, a leading North American supplier of specialty ingredients, the company reports. 

Nutrition & Health News

Shifting OTC landscape: P&G acquires Merck’s consumer health unit in US$4.2bn deal

20 Apr 2018 --- Procter & Gamble (P&G) has acquired Merck KGaA’s, Darmstadt, Germany, consumer health unit in a US$4.2 billion acquisition that hopes to boost P&G’s health care capabilities, such as with vitamins and supplements, and give them a stronger foothold in global markets.

Nutrition & Health News

MenaQ7 Full Spectrum K2 closest ingredient to dietary cheese intake, study finds

20 Apr 2018 --- Based on a global state of vitamin K2 deficiency and the strong evidence showing it is a cardio-protective nutrient, researchers recommend cheese as a component of a heart-healthy diet due to its vitamin K2 content. However, for those unable to consume enough cheese daily, NattoPharma has introduced its MenaQ7 Full Spectrum K2, which aims to deliver the range of menaquinones found in foods.

Nutrition & Health News

Weekly Digest: Omega 3 fatty acids health halo widens, NP Nutra organics line gets green boost

20 Apr 2018 --- The past seven days in the Nutrition world has seen research findings suggesting that omega 3 fatty acid supplementation could protect against the potential negative outcomes of smoking during pregnancy, such a preterm birth. Regarding new product launches, Nature’s Power Nutraceuticals corp (NP Nutra) has added two new powders to their sustainable, organic, green ingredients line in honor of world Earth day; Cambridge Commodities has released a customizable range of vitamin and mineral blends, coined Blendev, and off the back of successful product launches this year, Rousselot and Peptan commit to future innovations through customer engagement days. Lastly, Lycored has released its innovative plans for engaging customers at Vitafoods: with an interactive installation which tells the story of lycopene, a carotenoid found in tomatoes.

Nutrition & Health News

Bone and joint health: Consumer demands and promising ingredients

19 Apr 2018 --- Mobility, which incorporates bone and joint health, is becoming a key concern for a range of demographics. NutritionInsight spoke with a number of key suppliers in the bone and joint health space about the key ingredients to look out for, as well as some key consumer demands driving innovation in this space.

More Articles
URL : http://www.nutritioninsight.com:80/news/optibiotix-signs-major-supply-agreement-for-its-microbiome-modulating-cholesterol-reduction-probiotic.html